Haleon is a public company limited
United Kingdom · GB00BMX86B70 · reports in GBP · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue −1.8% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 10% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 51% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in GBP.
£11.0B
revenue
22%
operating margin
£1.7B
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | £10.9B | £11.3B | £11.2B | £11.0B |
| Operating profit | £1.8B | £2.0B | £2.2B | £2.4B |
| Net profit to shareholders | £1.1B | £1.0B | £1.4B | £1.7B |
| Earnings per share | £0.12 | £0.11 | £0.16 | £0.19 |
| Cash from operations | £2.1B | £2.1B | £2.3B | £2.6B |
| Capital spending | £304M | £234M | £250M | £322M |
| Cash | £684M | £1.0B | £2.3B | £1.3B |
| Total assets | £34.8B | n/a | £34.3B | £32.6B |
| Equity | £16.5B | £16.7B | £16.2B | £16.5B |
What they do
In the company's own words, from the annual report.
Our purpose: to deliver better everyday health with humanity
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.